A new pharmacological role for donepezil: attenuation of morphine-induced tolerance and apoptosis in rat central nervous system
© Sharifipour et al.; licensee BioMed Central Ltd. 2014
Received: 17 September 2013
Accepted: 20 January 2014
Published: 23 January 2014
Tolerance to the analgesic effect of opioids is a pharmacological phenomenon that occurs after their prolonged administration. It has been shown that morphine-induced tolerance is associated with apoptosis in the central nervous system and neuroprotective agents which prevented apoptosis signaling could attenuate tolerance to the analgesic effects. On the other hand donepezil, an acetylcholinesterase inhibitor, has been reported to have neuroprotective effects. Therefore in this study, the effect of systemic administration of donepezil on morphine-induced tolerance and apoptosis in the rat cerebral cortex and lumbar spinal cord was evaluated. Various groups of rats received morphine (ip) and different doses of donepezil (0, 0.5, 1, 1.5 mg/kg/day). Nociception was assessed using tail flick apparatus. Tail flick latency was recorded when the rat shook its tail. For apoptosis assay other groups of rats received the above treatment and apoptosis was evaluated by in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method.
The results showed that administration of donepezil (0.5, 1, 1.5 mg/kg, ip) delayed the morphine tolerance for 9, 12 and 17 days, respectively. Furthermore pretreatment injection of donepezil attenuated the number of apoptotic cells in the cerebral cortex and lumbar spinal cord compared to the control group.
In conclusion, we found that systemic administration of donepezil attenuated morphine-induced tolerance and apoptosis in the rat cerebral cortex and lumbar spinal cord.
KeywordsApoptosis Donepezil Morphine Tolerance
Prolonged exposure to opioids such as morphine results in the development of analgesic tolerance, and significantly limits the clinical usage of opioids. The neurobiological mechanisms underlying the development of opioid tolerance are multifaceted and are not completely understood. During the past decades, many studies have focused to clarify the mechanisms involved in morphine tolerance. In addition, it has been shown that apoptotic cell death would be induced in association with the development of morphine tolerance [1, 2]. Apoptosis, or program med cell death, is an active process of normal cell death during development and also occurs as a consequence of the cytotoxic effect of various neurotoxins . In vitro studies indicated that exposure to opioid receptor agonists increases their vulnerability to death by apoptotic mechanisms [4, 5]. Other studies have demonstrated that chronic morphine administration in rats is associated with remarkable significant changes in the key proteins involved in the apoptosis signaling which collectively leads to induction of apoptosis [2, 6–10].
There are several lines of evidence indicating the roles of excitatory amino acid receptors in the development of tolerance to the antinociceptive action of morphine. Numerous studies have demonstrated that N-methyl-D- aspartate receptor (NMDAR) antagonists and blockers have the ability to prevent the development of opioid-induced tolerance and dependence [11–15]. Other studies have shown that activation of NMDARs can lead to neurotoxicity under many situations [16, 17]. For instance, peripheral nerve injury has been shown to activate spinal cord NMDARs, which results in neuronal cell death by means of apoptosis [18, 19]. On the other hand, it has been reported that up-regulation of pro-apoptotic factors was inhibited when morphine was co-administered with the noncompetitive NMDAR antagonist, MK-801 . Taking together the above studies demonstrated that there is a significant relationship between opioid-induced tolerance and apoptosis.
More recently donepezil has been found to have neuroprotective effects. Donepezil is a specific, noncompetitive and reversible inhibitor of acetylcholine–esterase (AChE). AChE inhibitors are currently used to treat Alzheimer’s disease (AD). Previous studies demonstrated that AChE inhibitors, such as donepezil and galantamine, exert a protective effect via the nicotinic acetylcholine receptor (nAChR)-mediated cascade [21, 22]. In addition, it has been reported that AChE inhibitors inhibit the progress of brain atrophy in AD , indicating the attenuation of neuronal death in the brain of the patients.
Findings of the previous studies showed that AChE receptor inhibitors provide neuroprotection against glutamate-induced excitotoxicity by stimulating the phosphatidylinositol-3 kinase (PI3K) signaling pathway [21, 24]. In the present study, we investigated the effect of donepezil on morphine-induced apoptosis in the rat cerebral cortex and lumbar spinal cord during the development of tolerance to the analgesic effects of morphine.
Male Wistar rats (n = 168) weighing 250–300 g were used. The animals were housed in a temperature-controlled environment (24 ± 0.5°C) and kept on a 12 h light/dark cycle (light on 08:00 am) with free access to food and water. All experiments were in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85–23, revised 1985) and were approved by the research and ethics committee of Kurdistan University of Medical Sciences.
The experimental groups for behavioral & immunohistological evaluations
Treatment groups (n = 8 per group)
Saline (1 ml/kg, ip)
Morphine (10 mg/kg, ip) + Donepezil (0, 0.5, 1, 1.5 mg/kg, ip)
The most effective dose of Donepezil (1.5 mg/kg, ip) for 14 days
Groups for dose–response curves:
Saline (1 ml/kg, ip)
Animals received opposite treatments for 14 days, on 15th day, in separate groups logarithmic doses of morphine (1 or 100 mg/kg, ip) were administered to generate analgesic dose–response curves
Morphine (10 mg/kg, ip) + donepezil (0, 1.5 mg/kg, ip)
Morphine (10 mg/kg, ip) + MK801(0.1 mg/kg, ip)
Saline (1 ml/kg, ip) for 14 days
Morphine (10 mg/kg, ip) + Donepezil (0, 0.5, 1, 1.5 mg/kg, ip) for 14 days
The most effective dose of Donepezil (1.5 mg/kg, ip) for 14 days
Morphine (10 mg/kg, ip) + MK-801(0.1 mg/kg) for 14 days
Morphine sulfate (Darupakhsh, Iran) (1, 10, 100 mg/kg, ip) was dissolved in normal saline and injected using 1-ml insulin syringes. Donepezil (Sigma- Aldrich, Inc.) (0.5, 1, and 1.5 mg/kg) was dissolved in sterile 0.9% normal saline. Dizocilpine (MK801) (Sigma-Aldrich) (0.1 mg/kg) was dissolved in in sterile 0.9% normal saline. Solutions were prepared freshly on the days of the experiment.
Induction of tolerance to the analgesic effect of morphine
To induce tolerance to the analgesic effect of morphine, rats (n = 8 per group) were injected with morphine (10 mg/kg, ip) once a day (at morning: 10 am) until tolerance induction. This dose has been found to cause profound analgesia with no side effects in normal rats and was also according to the our previous study . For evaluation of donepezil and MK801’s effect on morphine-induced tolerance, morphine was administered 30 minutes after the intraperitoneal (ip) injection of donepezil, MK801 or their vehicle every day.
Assessment of nociception
Baseline latency was determined once per day (average of three measurement) for each rat, before daily injection of morphine (10 mg/kg). After baseline determination, the drugs or their vehicle were administered, 30 min later the morphine was injected and finally the post-drug latency was measured after 30 min. The %MPE was then calculated for that day. Every day the baseline and latency time were registered and %MPE was calculated every day. The experiments continued until there was no significant difference in %MPE between the vehicle- or drug-treated groups (tolerant animals) and the saline group .
Evaluation of tolerance induction
To evaluate the induction of tolerance, groups of rats received saline or morphine + saline or morphine + donepezil (the most effective dose) once a day for 14 days, and then logarithmic doses of morphine administrated to generate analgesic dose–response curves (according to the experimental groups table). In analgesic dose–response curves, morphine antinociceptive 50% effective dose (ED50) values for each of the drug groups were derived using linear regression of%MPE of the logaritmic doses of morphine. Differences in the ED50 estimations were determined using the confidence interval method at P <0.05 .
For the in situ terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end-labeling (TUNEL) assay, all animals (n = 8) received the above noted treatment regimens. On the day of tolerance completion in the control group (day 14th) and 2 h after the last dose of vehicle or treatment, the animals were euthanized by injection of ketamine and midazolam and perfused transcardially first with 0.9% saline (NaCl). Then cerebral cortexes and lumbar spinal cords were immediately dissected and fixed overnight at 4°C in the fixative solution (4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS), pH adjusted to 7.4). Following fixation, these tissues were cryoprotected in 10%, 20% and 30% sucrose (in PBS) overnight at 4°C. Subsequently, the tissues were transferred to Tissue-Tek OCT (Sakura FineTek, Gardena, CA) embedding compound inside the plastic molds. The blocks were stored at -70°C until cutting time.
Detection of apoptotic cells
After fixation and OCT embedding, the samples were cut into 3 μm-thick with a Cryocut apparatus (Leica 1800, Germany). For the TUNEL assay, an in situ Cell Death Detection kit (Roche Applied Science, Cat # 11 684 817 910) was used. This method allows us to examine the topographic distribution of apoptotic cells within the cerebral cortex and lumbar spinal cord. The tissue sections were stained according to the manufacturer’s instructions. Briefly, these sections were rinsed in series by fixation solution (4% paraformaldehyd in PBS, pH = 7.4) for 20 min at room temperature (RT) washing buffer (PBS) for 30 min, blocking solution (3% H2O2 in methanol) for 10 min at 15 to 25°C and permeabilization solution (0.1% triton x-100 in 0.1% sodium citrate) for 2 min on ice (2 to 8°C) to increase the permeability. After being rinsed twice in PBS, the sections pretreated with proteinase K (Roche, Germany) for 30 min at 37°C. Then, these sections were exposed to the TUNEL reaction mixture, which contains terminal deoxynucleotidyl transferase and nucleotides including fluorescein isothiocyanate-labeled dUTP for 60 min at 37°C in a dark, humidified atmosphere. After that, an anti-fluorescein peroxidase (POD)-linked antibody was added, followed by incubation for 30 min at 37°C. Finally, the reaction product was visualized by 3,3 diaminobenzidine tetrahydrochloride (DAB) incubation for 15 min at RT, and the slides were then counterstained with toluidine blue. A sub-population of apoptotic cells, scattered throughout the tissue section, was intensely stained (brown) by the TUNEL treatment. The number of apoptotic cells was counted using an Olympus IX71 microscope (40× objective) over 30 fields by a person who was blind to the treatment.
Behavioral data are expressed as the mean of %MPE ± sem of eight rats per group. Student’s t-test or one-way analyses of variance followed by Tukey’s test were used to analyze statistical significance in two or multiple comparisons respectively. P values <0.05 were considered to be significant in all analyses.
*P < 0.05, **P < 0.01, and ***P < 0.001 indicate a significant difference as compared with the saline group for that day. The histological data (cell counting) from cerebral cortexes and spinal cords sections were averaged and are expressed as mean ± sem.
Induction of tolerance to the antinociceptive effect of morphine
Evaluation the effect of donepezil on morphine-induced tolerance to the analgesic effect
Effect of donepezil on morphine-induced apoptosis
The results of the present study showed that chronic administration of morphine for 14 days induced tolerance to its analgesic effects, while administration of donepezil (0.5, 1 and 1.5 mg/kg, ip) decreased the development of this tolerance by shifting the first day of established tolerance from the 14th to the 23th, 26th and 31th day respectively. Also the results indicated that there was a significant shift to the left in the dose–response curve as well as a decrease in the antinociceptive 50% effective dose (ED50) of morphine for animals who received morphine and donepezil (1.5 mg/kg) compared to the control which means that donepezil prevented the shifting of dose–response curve and ED50 to the right. Moreover, administration of donepezil (1.5 mg/kg) alone had no significant analgesic effect (Additional file 1) which means that donepezil was not simply enhancing morphine analgesia through an additive mechanism.
Over a decade, it has been reported that chronic morphine administration can increase glutamate release in the CNS [15, 27]. Importantly, excessive release and accumulation of glutamate, which is associated with an increase in the level of intracellular calcium, plays an important role in CNS injury and neurodegenerative diseases .
Several lines of evidence suggest that N-methyl-D-aspartate (NMDA) glutamate receptors (NMDARs) are involved in the plasticity that arises from long-term administration of morphine [15, 29–31]. The initial evidence supporting this idea was provided by Trujillo and Akil who reported that the NMDA receptor antagonist, MK-801, inhibited the development of tolerance to the antinociceptive effect of morphine without affecting acute morphine antinociception . After this discovery, numerous studies have demonstrated that a variety of NMDA receptor antagonists have the ability to inhibit the development of opiate tolerance and dependence [11, 14, 15, 29–32]. In this study the effect of donepezil was compared to MK801. MK801 is an NMDA receptor antagonist with well-known neuroprotective effect that prevented tolerance to the analgesic effect of opioids so we used this agent as a gold standard.
On the other hand, in the cerebrocortical nerve terminals, donepezil has been found to decrease in glutamate-induced Ca2+ influx in the cerebral cortex and the spinal cord of the rat . It has also been reported that high concentrations of donepezil can attenuate excitatory amino acid receptor activation and decrease the excitability of the postsynaptic cell membrane [33, 34].
Previous studies demonstrated that both morphine tolerance and the associated neuronal apoptosis share a common cellular mechanism. In line with these findings, it has been reported that MK-801 blocks both tolerance and apoptosis . Furthermore, activation of NMDARs has been shown to initiate intracellular pathways leading to apoptotic cell death. Glutamate and NMDA can cause intracellular Ca2+ influx, activation of Ca2+-dependent enzymes such as nitric oxide synthase and production of toxic oxygen radicals leading to cell death .
Our results in the present study showed that prolonged exposure to morphine induced apoptotic cell death in the cerebral cortex and lumbar spinal cord. These findings confirmed the results of us and others, indicating that chronic morphine administration significantly increases apoptosis in the rat cerebral cortex and lumbar region of the spinal cord [7–9]. On the other hand, co-administration of donepezil and morphine delayed the onset of morphine-induced tolerance and significantly decreased the average number of TUNEL-positive cells.
Other studies have demonstrated that chronic treatment of rats with morphine (to induce tolerant and dependent states) is associated with a remarkable up-regulation of the pro-apoptotic Fas receptor, as well as intracellular pro-apoptotic elements such as caspase-3, combined with an opposing moderate down-regulation of the anti-apoptotic oncoprotein Bcl-2 [2, 6]. Although our findings showed the beneficial effect of donepezil on morphine-induced apoptosis but to clarify the cellular mechanisms and identify the markers involved in apoptosis pathways, further studies are needed.
It is well-known that opioid administration is often accompanied by peripheral and central nervous system anticholinergic side effects, such as dry mouth, constipation, urinary hesitancy, sedation, sleep disruption, and respiratory depression. In a previous study donepezil was reported to be useful in the treatment of daytime sedation, associated with the use of opiate analgesics in cancer patients . From the clinical point of view, donepezil as a cholinergic stimulating drug which has shown to be very well tolerated in patients is a promising agent for attenuating tolerance and sedation as two common and potentially dose-limiting side effects of the opiate analgesics. Therefore it is recommended to study the clinical effectiveness of donepezil along with opioids in cancer patients.
In conclusion, we found that donepezil as a neuroprotective agent prevented morphine-induced tolerance to the analgesic effects. Also it has been concluded that donepezil could attenuate apoptosis in the cerebral cortex and lumbar spinal cord which might be in association with behavioral effects.
The authors would like to thank Deputy of Research of Kurdistan University of Medical Sciences for financial supports.
- Ahlemeyer B, Krieglstein J: Stimulation of 5-HT1A receptor inhibits apoptosis induced by serum deprivation in cultured neurons from chick embryo. Brain Res. 1997, 777: 179-86.View ArticlePubMedGoogle Scholar
- Mao J, Sung B, Ji RR, Lim G: Neuronal apoptosis associated with morphine tolerance: evidence for an opioidinduced neurotoxic mechanism. J Neurosci. 2002, 22: 7650-7661.PubMedGoogle Scholar
- Sastry PS, Rao KS: Apoptosis and the nervous system. J Neurochem. 2000, 74: 1-20.View ArticlePubMedGoogle Scholar
- Dawson G, Dawson SA, Goswami R: Chronic exposure to kappa-opioids enhances the susceptibility of immortalized neurons (F-11kappa 7) to apoptosis-inducing drugs by a mechanism that may involve ceramide. J Neurochem. 1997, 68: 2363-2370.View ArticlePubMedGoogle Scholar
- Yin D, Mufson RA, Wang R, Shi Y: Fas-mediated cell death promoted by opioids. Nature. 1999, 397: 218-10.1038/16612.View ArticlePubMedGoogle Scholar
- Boronat MA, Garcia-Fuster MJ, Garcia-Sevilla JA: Chronic morphine induces up-regulation of the proapoptotic Fas receptor and down-regulation of the antiapoptotic Bcl-2 oncoprotein in rat brain. Br J Pharmacol. 2001, 134: 1263-1270. 10.1038/sj.bjp.0704364.PubMed CentralView ArticlePubMedGoogle Scholar
- Hassanzadeh K, Habibi-asl B, Roshangar L, Nemati M, Ansarin M, Farajnia S: Intracerebroventricular administration of riluzole prevents morphine-induced apoptosis in the rat lumbar spinal cord. Pharmacol Rep. 2010, 62: 664-673.View ArticlePubMedGoogle Scholar
- Hassanzadeh K, Habibi-Asl B, Farajnia S, Roshangar L: Minocycline prevents morphine-induced apoptosis in rat cerebral cortex and lumbar spinal cord: a possible mechanism for attenuating morphine tolerance. Neurotox Res. 2011, 19: 649-659. 10.1007/s12640-010-9212-0.View ArticlePubMedGoogle Scholar
- Hassanzadeh K, Roshangar L, Habibi-asl B, Farajnia S, Izadpanah E, Nemati M, Arasteh M, Mohammadi S: Riluzole prevents morphine-induced apoptosis in rat cerebral cortex. Pharmacol Rep. 2010, 62: 664-673.View ArticlePubMedGoogle Scholar
- Mayer DJ, Mao J, Holt J, Price DD: Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA. 1999, 96: 7731-7736. 10.1073/pnas.96.14.7731.PubMed CentralView ArticlePubMedGoogle Scholar
- Habibi-Asl B, Hassanzadeh K, Khezri E, Mohammadi S: Evaluation the effects of dextromethorphan and midazolam on morphine induced tolerance and dependence in mice. Pak J Biol Sci. 2008, 11: 1690-1695. 10.3923/pjbs.2008.1690.1695.View ArticleGoogle Scholar
- Gracy KN, Svingos AL, Pickel VM: Dual ultrastructural localization of mu-opioid receptors and NMDA-type glutamate receptors in the shell of the rat nucleus accumbens. J Neurosci. 1997, 17: 4839-4848.PubMedGoogle Scholar
- Habibi-Asl B, Hassanzadeh K, Vafai H, Mohammadi S: Development of morphine induced tolerance and withdrawal symptoms is attenuated by lamotrigine and magnesium sulfate in mice. Pak J Biol Sci. 2009, 12: 798-803. 10.3923/pjbs.2009.798.803.View ArticlePubMedGoogle Scholar
- Habibi-Asl B, Hassanzadeh K, Moosazadeh S: Effects of ketamine and magnesium on morphine induced tolerance and dependence in mice. DARU. 2005, 13: 110-115.Google Scholar
- Trujillo KA: The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity. Neurotox Res. 2002, 4: 373-391. 10.1080/10298420290023954.View ArticlePubMedGoogle Scholar
- Rothman SM, Olney JW: Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986, 19: 105-111. 10.1002/ana.410190202.View ArticlePubMedGoogle Scholar
- Salinska E, Danysz W, Lazarewicz JW: The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005, 43: 322-339.PubMedGoogle Scholar
- Mao J, Price DD, Zhu J, Lu J, Mayer DJ: The inhibition of nitric oxide-activated poly(ADP-ribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat. Pain. 1997, 72: 355-366. 10.1016/S0304-3959(97)00063-8.View ArticlePubMedGoogle Scholar
- Whiteside GT, Munglani R: Cell death in the superficial dorsal horn in a model of neuropathic pain. J Neurosci Res. 2001, 64: 168-173. 10.1002/jnr.1062.View ArticlePubMedGoogle Scholar
- Habibi-Asl B, Hassanzadeh K, Charkhpour M: Central administration of minocycline and riluzole prevents morphine-induced tolerance in rats. Anesth Analg. 2009, 109: 936-942. 10.1213/ane.0b013e3181ae5f13.View ArticlePubMedGoogle Scholar
- Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T: Akaike A: alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem. 2001, 276: 13541-13546.PubMedGoogle Scholar
- Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A: Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther. 2003, 306: 772-777. 10.1124/jpet.103.050104.View ArticlePubMedGoogle Scholar
- Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E: Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease?. Am J Psychiatry. 2005, 162: 676-682. 10.1176/appi.ajp.162.4.676.View ArticlePubMedGoogle Scholar
- Asomugha C, Linn D, Linn C: ACh receptors link two signaling pathways to neuroprotection against glutamate-induced excitotoxicity in isolated RGCs. J Neurochem. 2010, 112: 214-226. 10.1111/j.1471-4159.2009.06447.x.PubMed CentralView ArticlePubMedGoogle Scholar
- D’ Amour FE, Smith DL: A method for determining loss of pain sensation. J Pharmacol Exp Ther. 1941, 72: 74-79.Google Scholar
- McCarthy RJ, Kroin JS, Tuman KJ, Penn RD, Ivankovich AD: Antinociceptive potentiation and attenuation of tolerance by intrathecal co-infusion of magnesium sulfate and morphine in rats. Anesth Analg. 1998, 86: 830-836.PubMedGoogle Scholar
- Bobula B, Hess G: Effects of morphine and methadone treatments on glutamatergic transmission in rat frontal cortex. Pharmacol Rep. 2009, 61: 1192-1197.View ArticlePubMedGoogle Scholar
- Wang SJ, Wang KY, Wang WC: Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience. 2004, 125: 191-201. 10.1016/j.neuroscience.2004.01.019.View ArticlePubMedGoogle Scholar
- Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991, 251: 85-87. 10.1126/science.1824728.View ArticlePubMedGoogle Scholar
- Trujillo KA: Effects of non-competitive N-methyl-d-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacol. 1995, 13: 301-307. 10.1016/0893-133X(95)00088-U.View ArticleGoogle Scholar
- Mao J: NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Rev. 1999, 30: 289-304. 10.1016/S0165-0173(99)00020-X.View ArticlePubMedGoogle Scholar
- Habibi-Asl B, Hassanzadeh K: Effects of ketamine and midazolam on morphine induced dependence and tolerance in mice. DARU. 2004, 12: 101-105.Google Scholar
- Cao YJ, Dreixler JC, Couey JJ, Houamed KM: Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole. Eur J Pharmacol. 2002, 449: 47-54. 10.1016/S0014-2999(02)01987-8.View ArticlePubMedGoogle Scholar
- Centonze D, Calabresi P, Pisani A, Marinelli S, Marfia GA, Bernardi G: Electrophysiology of the neuroprotective neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacol. 1998, 37: 1063-1070. 10.1016/S0028-3908(98)00081-1.View ArticleGoogle Scholar
- Tamura Y, Sato Y, Akaike A, Shiomi H: Mechanisms of cholecystokinin-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 1992, 592: 317-325. 10.1016/0006-8993(92)91691-7.View ArticlePubMedGoogle Scholar
- Slatkin NE, Rhiner M: Treatment of opiate-related sedation: utility of the cholinesterase inhibitors. J Support Oncol. 2003, 1: 53-63.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.